LENZ Therapeutics Hits New 52-Week Low at $11.48 Amidst Significant Decline

LENZ Therapeutics, Inc., a microcap player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 11.48 as of February 23, 2026. This significant decline highlights the company's ongoing struggles, particularly in the context of its financial performance over the past year. The stock has faced considerable challenges, with a one-year performance reflecting a decrease of 53.53%, starkly contrasting with the S&P 500's positive return of 12.95%. The company's financial metrics indicate a loss-making position, with a pre-tax profit of USD -14.41 million, marking a decline of 20.76%. Additionally, the net profit has also reached a low of USD -14.91 million. LENZ Therapeutics currently holds a market capitalization of USD 363 million and exhibits a price-to-book ratio of 1.87. However, the company has not provided a dividend yield, and its return on equity stands at a notably negative figure. These indicators suggest a challenging environment for LENZ Therapeutics as it navigates its current market position.